NDLI: SDG indicator 3.b.3 – an analysis of its robustness and challenges for measuring access to medicines for children

Content Provider	Springer Nature : BioMed Central
Author	Joosse, I. R. Wirtz, V. J. van Mourik, A. T. Wagner, B. A. Mantel-Teeuwisse, A. K. Suleman, F. van den Ham, H. A.
Abstract	Background Sustainable Development Goal (SDG) indicator 3.b.3 monitors progress in medicines’ accessibility for adults and has significant limitations when applying to medicines for children. An adapted indicator methodology was developed to fill this gap, but no proof of its robustness exists. We provide this evidence through sensitivity analyses. Methods Data on availability and prices of child medicines from ten historical datasets were combined to create datasets for analysis: Dataset 1 (medicines selected at random) and Dataset 2 (preference given to available medicines, to better capture affordability of medicines). A base case scenario and univariate sensitivity analyses were performed to test critical components of the methodology, including the new variable of number of units needed for treatment (NUNT), disease burden (DB) weighting, and the National Poverty Line (NPL) limits. Additional analyses were run on a continuously smaller basket of medicines to explore the minimum number of medicines required. Mean facility scores for access were calculated and compared. Results The mean facility score for Dataset 1 and Dataset 2 within the base case scenario was 35.5% (range 8.0–58.8%) and 76.3% (range 57.2–90.6%). Different NUNT scenarios led to limited variations in mean facility scores of + 0.1% and -0.2%, or differences of + 4.4% and -2.1% at the more critical NPL of $5.50 (Dataset 1). For Dataset 2, variations to the NUNT generated differences of + 0.0% and -0.6%, at an NPL of $5.50 the differences were + 5.0 and -2.0%. Different approaches for weighting for DB induced considerable fluctuations of 9.0% and 11.2% respectively. Stable outcomes with less than 5% change in mean facility score were observed for a medicine basket down to 12 medicines. For smaller baskets, scores increased more rapidly with a widening range. Conclusion This study has confirmed that the proposed adaptations to make SDG indicator 3.b.3 appropriate for children are robust, indicating that they could be an important addition to the official Global Indicator Framework. At least 12 child-appropriate medicines should be surveyed to obtain meaningful outcomes. General concerns that remain about the weighting of medicines for DB and the NPL should be considered at the 2025 planned review of this framework.
Related Links	https://bmchealthservres.biomedcentral.com/counter/pdf/10.1186/s12913-023-09554-w.pdf
Ending Page	11
Page Count	11
Starting Page	1
File Format	HTM / HTML
ISSN	14726963
DOI	10.1186/s12913-023-09554-w
Journal	BMC Health Services Research
Issue Number	1
Volume Number	23
Language	English
Publisher	BioMed Central
Publisher Date	2023-06-03
Access Restriction	Open
Subject Keyword	Public Health Health Administration Health Informatics Nursing Research Access to medicines Child medicines Child health Sustainable development goals Indicator Affordability Availability
Content Type	Text
Resource Type	Article
Subject	Health Policy

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study.

Availability, prices and affordability of selected essential medicines in Jordan: a national survey

Access to essential and innovative anti-cancer medicines: a longitudinal study in Nanjing, China

A systematic scoping review of medicine availability and affordability in Africa

Availability and affordability of anticancer medicines at cancer treating hospitals in Rwanda

Parents’ and guardians’ perceptions on availability and pricing of medicines and healthcare for children in eThekwini, South Africa – a qualitative study

Where are we now: assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all

Availability and affordability of priority lifesaving maternal health medicines in Addis Ababa, Ethiopia

Availability, price, and affordability of diabetes mellitus and thyroid dysfunction medicines in South Wollo zone, Northeast Ethiopia

SDG indicator 3.b.3 – an analysis of its robustness and challenges for measuring access to medicines for children

Similar Documents

Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study.

Availability, prices and affordability of selected essential medicines in Jordan: a national survey

Access to essential and innovative anti-cancer medicines: a longitudinal study in Nanjing, China

A systematic scoping review of medicine availability and affordability in Africa

Availability and affordability of anticancer medicines at cancer treating hospitals in Rwanda

Parents’ and guardians’ perceptions on availability and pricing of medicines and healthcare for children in eThekwini, South Africa – a qualitative study

Where are we now: assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all

Availability and affordability of priority lifesaving maternal health medicines in Addis Ababa, Ethiopia

Availability, price, and affordability of diabetes mellitus and thyroid dysfunction medicines in South Wollo zone, Northeast Ethiopia

SDG indicator 3.b.3 – an analysis of its robustness and challenges for measuring access to medicines for children